Evidence map›Paper›PMID 26026052›Full record

ArticleMolecular cancer therapeutics2015

The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.

Payel Chatterjee, Gaurav S Choudhary, Turkeyah Alswillah, Xiahui Xiong, Warren D Heston, Cristina Magi-Galluzzi, Junran Zhang, Eric A Klein, Alexandru Almasan

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. CBP/p300, a promising therapeutic target for prostate cancer.Journal of translational medicine · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Targeting DNA Damage Response in Prostate and Breast Cancer.International journal of molecular sciences · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Drugging the Cancers Addicted to DNA Repair.Journal of the National Cancer Institute · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Payel ChatterjeeDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. School of Biomedical Sciences, Kent State University, Kent, Ohio.
Gaurav S ChoudharyDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Pathology, Case Western Reserve University School of Medicine, Ohio.
Turkeyah AlswillahDepartment of Chemistry, Cleveland State University, Cleveland, Ohio.
Xiahui XiongDepartment of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Warren D HestonDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Cristina Magi-GalluzziGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. Robert J. Tomisch Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio.
Junran ZhangDepartment of Radiation Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Alexandru AlmasanDepartment of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. almasaa@ccf.org.
Kent State University · US

Funding

Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagyR01CA184137 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI ALMASAN, ALEXANDRU · 2015 to 2019
$1.8M
THE ROLE OF NEDD4-1 IN IGF-1R SIGNALINGR01CA154625 · NCI · WASHINGTON UNIVERSITY · PI ZHANG, JUNRAN · 2011 to 2016
$1.6M
Cdk-2 Independent role of cyclin E in Cell survivalR01CA127264 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI ALMASAN, ALEXANDRU · 2009 to 2013
$1.6M
NCI NIH HHS CA127264NCI NIH HHS CA154625NCI NIH HHS R01 CA127264NCI NIH HHS R01 CA154625NCI NIH HHS R01 CA184137
6 · The paper itself

Abstract

Exposure to genotoxic agents, such as ionizing radiation (IR), produces DNA damage, leading to DNA double-strand breaks (DSB); IR toxicity is augmented when the DNA repair is impaired. We reported that radiosensitization by a PARP inhibitor (PARPi) was highly prominent in prostate cancer cells expressing the TMPRSS2-ERG gene fusion protein. Here, we show that TMPRSS2-ERG blocks nonhomologous end-joining (NHEJ) DNA repair by inhibiting DNA-PKcs. VCaP cells, which harbor TMPRSS2-ERG and PC3 cells that stably express it, displayed γH2AX and 53BP1 foci constitutively, indicating persistent DNA damage that was absent if TMPRSS2-ERG was depleted by siRNA in VCaP cells. The extent of DNA damage was enhanced and associated with TMPRSS2-ERG's ability to inhibit DNA-PKcs function, as indicated by its own phosphorylation (Thr2609, Ser2056) and that of its substrate, Ser1778-53BP1. DNA-PKcs deficiency caused by TMPRSS2-ERG destabilized critical NHEJ components on chromatin. Thus, XRCC4 was not recruited to chromatin, with retention of other NHEJ core factors being reduced. DNA-PKcs autophosphorylation was restored to the level of parental cells when TMPRSS2-ERG was depleted by siRNA. Following IR, TMPRSS2-ERG-expressing PC3 cells had elevated Rad51 foci and homologous recombination (HR) activity, indicating that HR compensated for defective NHEJ in these cells, hence addressing why TMPRSS2-ERG alone did not lead to radiosensitization. However, the presence of TMPRSS2-ERG, by inhibiting NHEJ DNA repair, enhanced PARPi-mediated radiosensitization. IR in combination with PARPi resulted in enhanced DNA damage in TMPRSS2-ERG-expressing cells. Therefore, by inhibiting NHEJ, TMPRSS2-ERG provides a synthetic lethal interaction with PARPi in prostate cancer patients expressing TMPRSS2-ERG.

Indexed as

DNA End-Joining RepairAdaptor Proteins, Signal TransducingCell Cycle CheckpointsCell Cycle ProteinsCell Line, TumorChromatinDNA-Binding ProteinsDNA DamageHumansMaleNuclear ProteinsOncogene Proteins, FusionPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesProstatic NeoplasmsRadiation ToleranceAdaptor Proteins, Signal TransducingCell Cycle ProteinsChromatinDNA-Binding ProteinsMDC1 protein, humanNuclear ProteinsOncogene Proteins, FusionPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesTMPRSS2-ERG fusion protein, humanTrans-ActivatorsXRCC4 protein, human

Identifiers

PMID26026052
PMCPMC4529796
OpenAlexW2172085538

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.